NOVARTIS (CAIN457F2206)

By June 19, 2019 Closed

A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered i.v. compared to s.c. in patients with active rheumatoid arthritis despite treatment with methotrexate

Join the discussion 9 Comments

Leave a Reply